Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Instituto de Investigaciones Clínicas Bahia Blanca
Bahía Blanca, Argentina
CONEXA Investigacion Clinica S.A.
Buenos Aires, Argentina
Buenos Aires Macula S.A
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Instituto Médico Especializado (IME)
Buenos Aires, Argentina
Cicemo Srl
Buenos Aires, Argentina
Cardiología Palermo
Buenos Aires, Argentina
Nefra Mansilla
Buenos Aires, Argentina
Consultorio Medico Investigador Principal Dr Besada
Buenos Aires, Argentina
Glenny Corp. S.A.
Buenos Aires, Argentina
Start Date
December 1, 2025
Primary Completion Date
August 1, 2031
Completion Date
August 1, 2031
Last Updated
March 20, 2026
7,140
ESTIMATED participants
Orforglipron
DRUG
Placebo
DRUG
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT06926660
NCT06717698
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07450820